Chemical Blocking of Zinc Ions in CNS Increases Neuronal Damage Following Traumatic Brain Injury (TBI) in Mice

Peter Doering1*, Meredin Stoltenberg1, Milena Penkowa2, Jørgen Rungby3, Agnete Larsen1, Gorm Danscher1

1 Institute of Anatomy, Neurobiology, University of Aarhus, Aarhus, Denmark, 2 Section of Neuroprotection, Department of Neuroscience and Pharmacology, Faculty of Health Sciences, The Panum Institute, University of Copenhagen, Copenhagen, Denmark, 3 Department of Pharmacology, University of Aarhus, Aarhus, Denmark

Abstract

Background: Traumatic brain injury (TBI) is one of the leading causes of disability and death among young people. Although much is already known about secondary brain damage the full range of brain tissue responses to TBI remains to be elucidated. A population of neurons located in cerebral areas associated with higher cognitive functions harbours a vesicular zinc pool co-localized with glutamate. This zinc enriched pool of synaptic vesicles has been hypothesized to take part in the injurious signalling cascade that follows pathological conditions such as seizures, ischemia and traumatic brain injury. Pathological release of excess zinc ions from pre-synaptic vesicles has been suggested to mediate cell damage/death to postsynaptic neurons.

Methodology/Principal Findings: In order to substantiate the influence of vesicular zinc ions on TBI, we designed a study in which damage and zinc movements were analysed in several different ways. Twenty-four hours after TBI ZnT3-KO mice (mice without vesicular zinc) were compared to littermate Wild Type (WT) mice (mice with vesicular zinc) with regard to histopathology. Furthermore, in order to evaluate a possible neuro-protective dimension of chemical blocking of vesicular zinc, we treated lesioned mice with either DEDTC or selenite. Our study revealed that chemical blocking of vesicular zinc ions, either by chelation with DEDTC or accumulation in zinc-selenium nanocrystals, worsened the effects on the aftermath of TBI in the WT mice by increasing the number of necrotic and apoptotic cells within the first 24 hours after TBI, when compared to those of chemically untreated WT mice.

Conclusion/Significance: ZnT3-KO mice revealed more damage after TBI compared to WT controls. Following treatment with DEDTC or selenium an increase in the number of both dead and apoptotic cells were seen in the controls within the first 24 hours after TBI while the degree of damage in the ZnT3-KO mice remained largely unchanged. Further analyses revealed that the damage development in the two mouse strains was almost identical after either zinc chelation or zinc complexion therapy.

Introduction

Zinc is found in every cell of our body and is required for processes as diverse as gene expression, DNA synthesis, enzymatic catalysis, hormonal storage, tissue repair, neurotransmission and memory [1,2]. The majority of zinc ions in the brain (approximately 85%) are intimately bound in proteins, such as zinc finger proteins (DNA-binding proteins), enzymes and metallothioneins, while the rest (approximately 15%) are sequestered in presynaptic vesicles in the terminals of a special subset of neurons, called zinc enriched (ZEN) neurons [3–7].

ZEN neurons in the mammalian brain are primarily glutamatergic [8–10] and forebrain regions such as hippocampus, amygdala and neocortex are crowded with ZEN terminals [11]. The presynaptic zinc ions are located in a pool of synaptic vesicles. These vesicles are free or loosely bound and can be chelated by zinc chelators some of which are fluorescent [11], or captured as zinc-selenium nanocrystals and subsequently traced in brain sections at LM and EM levels [12,13]. The neocortex of rodents displays a dense and highly ordered selenium-AMG staining in the light microscope and reveals the presence of in vivo created zinc-selenium nanocrystals in the synaptic vesicles in the electron microscope [13]. The complex patterns of ZEN terminals in different parts of the brain and spinal cord have been described in several papers [14–16].

The physiological significance of zinc ions in the ZEN terminals is far from fully understood. It has been suggested that the zinc ions are released into the synaptic clefts [3,17–19] where they act as a neuro-modulating agent on one or more postsynaptic receptors [20,21].

In 1996 it was suggested that the zinc transporter 3 protein (ZnT3) was responsible for transport of zinc ions into the synaptic

* E-mail: pdj@neuro.au.dk
vesicles of the ZEN terminals [22]. Later studies confirmed that the ZnT3 protein is abundantly present in the ZEN mossy fibres and that the zinc transporter protein is located to the membranes of the synaptic vesicles and controls the amount of zinc in the synaptic vesicles [23,24]. ZnT3-KO mice lack the ZnT3 protein and hence these animals are completely void of zinc ions in their ZEN terminals. This finding is supported by the fact that the total zinc levels in the hippocampus and the neocortex have been reported to be reduced by 20% [23,25]. In harmony with former observations based on a temporary chemical binding of the vesicular zinc pool [26,27] or a reduced level of vesicular zinc following an adrenally induced loss of zinc ions [28] no major physiological and behavioural changes were found in studies comparing the ZnT3 mouse to the WT littermate. The only recorded important difference was that the ZnT3 mouse tends to be more seizure prone when treated with kainic acid [25,29].

In addition to influencing neuronal transmission vesicular zinc might contribute to neuronal injury under pathological circumstances where dys-homeostasis of vesicular zinc ions has been advocated to be partaker in the development of the neurodegenerative changes following brain damage [30].

Neuronal damage following TBI [31], ischemia [32,33] and seizures [34] has been hypothesized to be exacerbated as a result of a dynamic presynaptic release of zinc ions that subsequently transcend into postsynaptic neurons causing cell death.

The present study aims at scrutinizing this hypothesis using ZnT3-KO mice and WT controls, i.e. mice with and without vesicular zinc.

Materials and Methods

Animals

The ZnT3-KO and WT mice used were obtained by courtesy of Dr. R. Palminter.

The animals were kept in plastic cages in a room with a 12-hour light/dark cycle at 21–22°C and 50% humidity. They were fed Altromin No. 1324 (Spezialfutterwerke, Germany) ad libitum and had free access to tap water.

Ethics statement. All efforts were made to minimize animal suffering and the number of animals used. The experimental procedures followed were carried out in accordance with the regulations of the animal protection laws of Denmark.

A total of fifty-eight animals were sacrificed during this study (n = 58). The mice selected for chelation therapy were divided into six groups of five (n = 30). The mice selected for zinc Se AMG (ZnSeAMG) and FluoroJade B staining were divided into four groups of five (n = 20). Eight mice were selected for control sectioning (n = 8).

Temgesic (buprenorphin) was used as an analgesic throughout the procedures.

The Stereotactic Cut Lesion

The mice were deeply anaesthetized prior to the operation. The anaesthetic was used a combination of Ketaminol Vet. 50 mg/ml, 0.25 ml Narcaryl Vet. 20 mg/ml and 3.75 isotonic salt water. 0.1 ml per 10 gram bodyweight of the solution was injected intraperitoneally (IP). Each animal was observed closely for withdrawal reflexes as a test of satisfactory anaesthesia. Then it was placed in a small animal stereotaxic instrument designed to avoid introduction of micro-agents into the wound.

One hour before TBI, the animals chosen for chemical in situ capturing of zinc ions were anaesthetized with a Ketaminol/narcoxyl solution and IP injected with either 5 mg per kg bodyweight sodium selenite (Na2SeO3) or 150 mg per kg bodyweight diethylthiocarbamate (EDTDC). Sodium selenite and EDTDC were dissolved in deionised water in a concentration of 1 mg sodium selenite per 1 ml distilled water and 15 mg EDTDC per 1 ml distilled water. This low dose of EDTDC (150 mg/kg) only produces a temporary block of the vesicular zinc pattern which within a few hours is re-established, and doses up to 1000 mg/kg EDTDC are tolerated well [35]. Other studies have used doses of 200 mg/kg EDTDC without inducing and without recording apoptosis evaluated with TUNEL stain or evaluated histologically with either H&E or acid fuchsin stains [36,37].

The brains selected for TUNEL, caspase-3 or GFAP staining were post-fixed for at least one hour in a paraformaldehyde (PFA) solution. The newly dissected brains were placed in a 30% solution of sucrose until they sank to the bottom of the jar. The brains were then frozen with CO2 for a period of 2 min. Thereafter the tissues were placed in a cryostat and allowed to increase in temperature to −17°C. 30-μm-thick sections were cut in 5 series, placed on glass slides and stained with FJB according to the protocol (vide infra) or were counterstained with a 0.1% aqueous toluidine blue solution, lowered to the drilled furrow and then further lowered 1 mm, penetrating the neocortex, and gently moved 3 mm caudally. The major advantage of this procedure is that it is highly reproducible and that our model of TBI gives us access to specific target areas with high amounts of ZEN terminals.

The skin above the calvarium was sutured after the operation to avoid introduction of micro-agents into the wound.

Zinc Ion Capturing

One hour before TBI, the animals chosen for chemical in situ capturing of zinc ions were anaesthetized with a Ketaminol/narcoxyl solution and IP injected with either 5 mg per kg bodyweight sodium selenite (Na2SeO3) or 150 mg per kg bodyweight diethylthiocarbamate (EDTDC). Sodium selenite and EDTDC were dissolved in deionised water in a concentration of 1 mg sodium selenite per 1 ml distilled water and 15 mg EDTDC per 1 ml distilled water. This low dose of EDTDC (150 mg/kg) only produces a temporary block of the vesicular zinc pattern which within a few hours is re-established, and doses up to 1000 mg/kg EDTDC are tolerated well [35]. Other studies have used doses of 200 mg/kg EDTDC without inducing and without recording apoptosis evaluated with TUNEL stain or evaluated histologically with either H&E or acid fuchsin stains [36,37].

From studies of retrograde axonal transport of zinc in rats and mice we have found that doses up to 8 mg/kg selenite are tolerated well at a survival time of 24 hours [14,38,39,40]. Thus 5 mg/kg selenite IP is considered a relatively safe dose unable to induce brain damage on its own.

Selenium was chosen as a chemical blocker of loosely bound and free zinc ions because of the long known fact that zinc ions react with selenide ions creating zin selenide molecules that again accumulate in zinc-selenium nanocrystals [12,40]. Furthermore, we have previously traced the ZEN terminals to the ultrastructural level applying the ZnSeAMG method, which makes a direct coupling of previous anatomical findings to the findings of the present study possible [41].

Zinc Tracing and FluoroJade B (FJB)

Twenty-four hours after TBI the animals chosen for zinc and FJB staining were re-anaesthetized and sacrificed by transcardial perfusion with a 3% glutaraldehyde solution (GA) in a 0.1% phosphate buffer solution for 3 min. The perfusion pressure was set at 140 mmHg.

Tissue Processing

The brains selected for TUNEL, caspase-3 or GFAP staining were quickly dissected, dehydrated through graded alcohol, imbedded in paraffin, and cut in series of 3 μm sections.

Brains selected for FJB staining (cryo-sectioning) were post-fixed for at least one hour in a paraformaldehyde (PEA) solution. The newly dissected brains were placed in a 30% solution of sucrose until they sank to the bottom of the jar. The brains were then frozen with CO2 for a period of 2 min. Thereafter the tissues were placed in a cryostat and allowed to increase in temperature to −17°C. 30-μm-thick sections were cut in 5 series, placed on glass slides and stained with FJB according to the protocol (vide infra) or were counterstained with a 0.1% aqueous toluidine blue solution, which within a few hours is re-established, and doses up to 1000 mg/kg EDTDC are tolerated well [35].
dehydrated in alcohol to xylene, and ultimately embedded in DEPEX and covered with a cover-glass.

**Autometallography (AMG)**

The AMG developer consists of a) 60 ml gum arabic solution (Bidinger, Aarhus, DK), b) 10 ml sodium citrate (23.5 g sodium citrate (Merck 6448, VWR, DK) to 100 ml distilled water), c) 15 ml reducing agent (0.85 g hydroquinone (Merck 4610, VWR, DK) dissolved in 15 ml distilled water at 40°C), and d) 15 ml of a solution containing silver ions (0.12 g silver lactate (Fluka 85210 supplied by Sigma-Aldrich, Vallensbæk, DK) in 15 ml distilled water at 40°C). Mix solution a (60 ml), solution b (10 ml), and solution c (15 ml) carefully in a 100 ml beaker. Add solution d (15 ml) immediately before use and mix thoroughly.

The AMG development takes place in a water bath at 26°C for 60–70 min under a dark hood. Development is stopped by replacing the developer with a 5% thiosulphate solution for 10 min. Finally, the tissue sections/slices are rinsed several times in distilled water [13,40].

**Tissue Slicing**

Tissue slices to be analysed for zinc staining at the light microscopical level were treated in accordance with the following two procedures, respectively:

1. For light microscopical analyses of thick sections the slices were placed in a 30% solution of sucrose until they sank to the bottom of the glass. The slices were then frozen with CO₂,

![Figure 1. Tracing of zinc using the ZnSeAMG method.](image-url)

(A) Cryo-section: Wild Type mouse 24 hours after TBI. Asterisks denote lesion tract; a distinct layering of the neocortex is noticeable. Closest to the lesion tract no AMG development is possible because all cells are severely damaged. This is shown as a little tint of white on both sides of the lesion tract. Scale bar: 1 mm. (B) Cryo-section: ZnT3-KO mouse 24 hours after TBI. Asterisks denote lesion. In the periphery of the lesion a number of ZnSe nanocrystals containing neurons are just visible. These somata marked neurons border the area between morphologically damaged tissue and morphologically intact tissue. (C) Semi-thin section: Wild Type mouse, a close-up of what is seen in A. There is a distinct neuropil stain; the tissue is oedematous with bleeding. The neurons are distorted, with vacuolation of their cytoplasm and some with eccentrically placed, pycnotic nuclei; none of the neuronal cell-bodies contain any ZnSe nanocrystals. Scale bar: 30 μm. (D1–2) Semi-thin sections: ZnT3-KO mouse. In the periphery of the lesion some neurons containing ZnSe nanocrystals in their somata can be seen. Going towards the lesion tract most cells are heavily distorted with condensed, eccentrically placed nuclei. The tissue is severely damaged with massive oedema. Scale bar: 30 μm. (E) Cryo-section: Wild Type mouse stained with FJB; fluorescent neurons border the lesion tract. Scale bar: 300 μm. (F) Cryo-section: ZnT3-KO mouse stained with FJB; numerous neurons line the lesion tract. Scale bar: 300 μm.

doi:10.1371/journal.pone.0010131.g001
placed in a cryostat, and allowed a temperature fall to $-17^\circ$C. After AMG development (see below), the sections were counterstained with a 0.1% solution of aqueous Toluidine blue ($pH$ 4.0), dehydrated in ascending concentrations of alcohol and xylene, embedded in DePex and covered with a cover-glass.

(2) For light microscopical analysis of zinc staining in semi-thin sections the slices were cut on a vibratome and the resulting 100-μm-thick sections were developed in AMG. The areas to be analysed were cut out, placed in osmium tetroxide (1% in phosphate buVer for 30 min) and embedded in Epon. From these Epon blocks 3-μm-thick sections were cut and counterstained with toluidine blue.

**FluoroJade B (FJB) Staining**

The FJB staining solution consists of: 10 mg of a stock solution of FJB dye powder in 100 ml of distilled water (0.01%). To make up 100 ml staining solution, 4 ml of the stock solution is added to 96 ml of 0.1% of acetic acid vehicle. This results in a final dye concentration of 0.0004%.

The tissues for FJB staining were cryo-proctected with sucrose 20-30% for 24 hours, frozen with CO$_2$ and cut in 30 μm sections on a cryostat. The sections were dried on a slide warmer at 50°C and placed on a slide warmer, set at 50°C briefly draining the slides vertically on a paper towel. They were each of three distilled water washes. Excess water was removed by pretreatment with 1% sodium hydroxide in 80% alcohol for 3 min and distilled water for 2 min. The treatment was a 0.02% potassium-permanganate solution for 10 min while being gently shaken on a “shaker” table. Finally the slides were yet again rinsed in distilled water for 2 min.

The slides were placed in a 0.0004% FJB solution for 20 min while being gently shaken, and subsequently rinsed for 1 min in each of three distilled water washes. Excess water was removed by briefly draining the slides vertically on a paper towel. They were then placed on a slide warmer, set at 50°C, for 5-10 min (until dry), and cleared by immersion in xylene for approximately 1 min before being cover-slipped with DPX, a non-aqueous, non-fluorescent plastic mounting media [42].

**Systemic Selenium and DETDC Treatment**

Twenty-four hours after TBI (and 25 hours after IP injections of selenite and DETDC, respectively), the animals were re-anaesthetized and sacrificed by transcardial perfusion with 4% PFA in a 0.1% phosphate buffer solution for 3 min. The perfusion pressure was set at 140 mmHg.

**In situ Detection of Apoptosis**

**In situ** detection of DNA fragmentation (TUNEL) Terminal deoxynucleotidyl transferase (TdT) - mediated deoxyuridine triphosphate (dUTP)-biotin nick end labelling (TUNEL) was performed using the Fragment End Labeling (FragEL) Detection Kit (Calbiochem, USA, code QIA33). The FragEL kit contains all the materials used below and each step was performed according to the manufacturer’s recommendations. Rehydrated sections were incubated with 20 μg/ml proteinase K for 20 min to strip off nuclear proteins. After immersion in an equilibration buVer for 20 min, the sections were incubated with TdT and biotin-labeled deoxynucleotides (dNTP-biotin) in a humidified chamber at 37°C for 90 min. This was followed by a wash buVer and the stop solution for 5 min at room temperature to stop the reaction. After washing in TBS and incubation in blocking buVer for 10 min the sections were incubated with peroxidase streptavidin for 30 min, and finally DAB was used as chromogen. The sections were counterstained with methyl-green. Negative control sections were treated similarly, but incubated in the absence of TdT enzyme, dNTP-biotin or peroxidase-streptavidin.

**Caspase-3**

The paraffin embedded sections were rehydrated according to standard procedures, after which they underwent heat-induced epitope retrieval and blocking as previously described in detail [43,44]. Sections were then incubated overnight at 4°C with the following primary antibody: Rabbit anti-caspase-3 (activated/cleaved caspase-3 as a marker of apoptosis) diluted 1:50 (Cell Signaling Techn. Inc., USA, cat. no.: 9661). On the second day the primary antibody was detected by incubating the sections for 30 min at room temperature with a biotinylated secondary antibody: anti-rabbit IgG (Sigma-Aldrich, cat. no.: 3275, diluted 1:400).

The staining was then visualized using a streptavidin-biotin-peroxidase complex (StreptABCComplex/HRP, Dako, Glostrup, DK, code K377) and a tyramide signal amplification (TSA)-kit (NEN, Life Science Products, Waltham, MA, USA, code NEL700A), which were applied following the manufacturer’s recommendations. Then, immunoreactions were visualized by using 0.015% H$_2$O$_2$ in 3,3-diaminobenzidine-tetrahydrochloride (DAB)/TBS for 10 min at room temperature.

**In situ Detection of Reactive Gliosis**

**GFAP.** The sections were incubated overnight at 4°C with the following primary antibody: Rabbit anti-GFAP (a marker of astrocytes) diluted 1:250 (Dako, DK, cat. no.: Z334). The primary antibody was detected using biotinylated secondary antibodies (incubation for 30 min at room temperature), followed by streptavidin-biotin-peroxidase complexing (StreptABCComplex/HRP, Dako, DK, code K377) and tyramide signal amplification (TSA)-kit (NEN, Life Science Products, USA, code NEL700A), according to the manufacturer’s recommendations. Finally, the immunoreactions were visualized using DAB as chromogen.

In all experiments, the extent of non-specific binding of antiserum was evaluated by omitting the primary antibody step. Results were considered only if those controls were negative.

**Cell Counts.** Positively stained cells were defined as cells with positive staining of the soma except in the case of TUNEL staining, where the apoptotic cells were defined as those with nuclear staining (nuclear TUNEL).

The cell counts were performed on five mice per group by the same investigator, who was blinded to the animals’ identity and treatment. The quantifications were used for statistical comparisons. Five sections per animal were collected from the lesioned hemisphere and counted. Every third section down through the lesion was collected, starting randomly on slides 1–3 until a total of 5 sections were obtained from each animal using the Cavalieri principle. A frame was superimposed on the border of the lesion

| Table 1. Students t-test. |
|--------------------------|
| TBI         | n = 5 | 95% | ci       |
| WT          | 570.6 | [348.16 793.04] |
| ZnT3        | 983.0 | [1301.80] |
| Diff        | -412.4| [-55.22] |

FluoroJade B staining of cryo sections. *Indicates statistically significant difference, p<0.05.

doi:10.1371/journal.pone.0010131.t001
Figure 2. Evaluation of apoptosis and reactive gliosis. The rows illustrate TUNEL stains in (A-F), GFAP stains in (G-L) and Caspase 3 stains in (M-R). All sections are paraffin sections 24 hours after TBI. (A) Wild Type mouse, not chelator treated. (B) Wild Type mouse treated with DEDTC 1 hour before TBI. An increased number of apoptotic neurons are seen. (C) Wild Type mouse treated with selenite 1 hour before TBI. Even more apoptotic neurons are lining the lesion tract. (D) ZnT3-KO mouse not chelator treated. Numerous apoptotic neurons are seen. (E) ZnT3-KO treated with DEDTC 1 hour before TBI. Still a number of apoptotic neurons are seen. (F) ZnT3-KO mouse treated with selenite prior to TBI. No major changes compared to the other ZnT3-KO sections are observed. (G) Wild-type mouse not chelator treated; some reactive cells are seen in the area. (H) Wild Type mouse treated with DEDTC 1 hour before TBI. No major changes are observed. (I) Wild Type mouse treated with selenite 1 hour before TBI. No major changes are observed. (J) ZnT3-KO mouse not chelator treated; some activated glia are seen. (K) ZnT3-KO mouse DEDTC treated 1 hour before TBI. The gliosis remains unchanged. (L) ZnT3-KO mouse selenite treated 1 hour before TBI. A massive increase in the reactive gliosis is seen with big amoeboid cells and increased staining intensity. (M) Wild Type mouse. Sparse Caspase 3 positive cells are seen near the lesion tract. (N) Wild Type mouse treated with DEDTC before TBI. More caspase 3 positive neurons are seen in the proximity of the lesion tract. (O) Wild Type mouse treated with selenite before TBI; a clear increase in the number of caspase 3 positive neurons is seen near the lesion. (P) ZnT3-KO mouse. Sparse Caspase 3 positive cells are seen near the lesion tract. (Q) ZnT3-KO mouse, treated with DEDTC before TBI. No significant increase in the number of Caspase 3 positive cells is observed. (R) ZnT3-KO mouse treated with selenite before TBI. A major increase in the number of positive cells is observed in the entire lesioned area. Scale bar: 300 μm.
doi:10.1371/journal.pone.0010131.g002
tract ranging into the lesional area where the damaged cells were counted.

All pictures used for counting procedures were taken in one session and all counting procedures were performed on light microscopic photographs taken using the ×20 objective on a Carl Zeiss Vision light microscope equipped with Carl Zeiss Imager.Z1 and an AxioCam MRc5 from AxioLab. Fixed settings and conditions were used to ensure proper comparison of the images.

Statistical Analysis

The average cell counts obtained from the Zinc/ FJB groups were compared using Students t-test. The groups used for chelation treatment and multiple comparisons were analysed using analysis of variance (ANOVA). All values are given as means ± SEM (with a 95% confidence interval [ci]), and the significance level was set at P<0.05.

Results

Autometallographic Analysis

In the ZnT3-KO mice the ZnSeAMG method revealed numerous neurons with silver enhanced zinc nanocrystals in their somata. After 24 hours the loaded neuronal somata were all found in the periphery of the lesion, marking the transition between TBI and with an AxioCam MRc5 from AxioLab. Fixed settings and conditions were used to ensure proper comparison of the images.

Opposite to this characteristic ZnT3-KO TBI AMG pattern the WT control mice were completely void of stained neuronal somata although clear signs of morphological cell damage were conspicuous.

Cell Death/FluoroJade B Neurons

Neuronal counting of FJB positive neurons and statistical analysis show that the ZnT3-KO mice have significantly more dead or dying neurons evaluated after 24 hours after TBI (Figure 1E, F). Students t-test revealed this to be a significant difference with P<0.05 (see Table 1).

Apoptotic Cell Death/TUNEL

In the groups not treated with DEDTC the TUNEL stains also reveal a significant difference in the number of apoptotic neurons between the WT and the ZnT3-KO mice, the latter having the majority of damaged neurons (Figure 2A, D). After chelation therapy the pattern of damage in the two stains resembles one another (Figure 2B, E & C, F) and the WT controls exhibit a significantly increased number of apoptotic neurons compared to WT animals not treated with DEDTC or selenite (compare Figure 2B, C to A). Table 2 summarizes the TUNEL results:

Table 3. GFAP; only the group o66–70 contains more GFAP positive cells although a tendency towards the cells becoming more GFAP positive after chelation therapy is noted.

| TBI          | n = 30 | mean    | 95% ci       |
|--------------|-------|---------|--------------|
| WT           | o41–45| n = 5   | 241.2 [164.01 318.39] |
| ZnT3         | o46–50| n = 5   | 478.8 [401.61 555.99] |
| WT + DEDTC   | o51–55| n = 5   | 532.2 [454.81 609.19] |
| ZnT3 + DEDTC | o56–60| n = 5   | 590.4 [513.21 667.59] |
| WT + selenite| o61–65| n = 5   | 588.3 [510.81 665.19] |
| ZnT3 + selenite| o66–70| n = 5 | 465.8 [388.61 542.99] |

Table 4. Caspase 3; the chelator treated groups o61–65 and o66–70 contains significantly more apoptotic neurons than the remaining groups.

| TBI          | n = 30 | mean    | 95% ci       |
|--------------|-------|---------|--------------|
| WT           | o41–45| n = 5   | 241.2 [164.01 318.39] |
| ZnT3         | o46–50| n = 5   | 478.8 [401.61 555.99] |
| WT + DEDTC   | o51–55| n = 5   | 532.2 [454.81 609.19] |
| ZnT3 + DEDTC | o56–60| n = 5   | 590.4 [513.21 667.59] |
| WT + selenite| o61–65| n = 5   | 588.3 [510.81 665.19] |
| ZnT3 + selenite| o66–70| n = 5 | 465.8 [388.61 542.99] |

doi:10.1371/journal.pone.0010131.t002

doio:10.1371/journal.pone.0010131.t004

Table 2. TUNEL; the group o46–50 has significantly more apoptotic neurons than o41–45, this difference equals after chelator application [o51–55,o56–60], [o61–65,o66–70].

| TBI          | n = 30 | mean    | 95% ci       |
|--------------|-------|---------|--------------|
| WT           | o41–45| n = 5   | 241.2 [164.01 318.39] |
| ZnT3         | o46–50| n = 5   | 478.8 [401.61 555.99] |
| WT + DEDTC   | o51–55| n = 5   | 532.2 [454.81 609.19] |
| ZnT3 + DEDTC | o56–60| n = 5   | 590.4 [513.21 667.59] |
| WT + selenite| o61–65| n = 5   | 588.3 [510.81 665.19] |
| ZnT3 + selenite| o66–70| n = 5 | 465.8 [388.61 542.99] |

doio:10.1371/journal.pone.0010131.t002

Table 3. GFAP; only the group o66–70 contains more GFAP positive cells although a tendency towards the cells becoming more GFAP positive after chelation therapy is noted.
Discussion

The finding that TBI exposed neurons of ZnT3-KO mice accumulate zinc ions in their somata and reveal significantly more damaged neurons by the FluoroJade B staining suggests that zinc ions, in complete contrast to what has been suggested until now, have protective qualities to the TBI aftermath. This interpretation was strengthened by the finding that the WT controls after TBI did not accumulate zinc ions in their neuronal somata, although the surrounding neuropil was teeming with ZEN terminals and further that the amount of dead neurons was significantly lower in the WT controls.

This notion was further supported by results from chemical binding of zinc ions. We found that although the ZnT3-KO mice had initially more damaged neurons, as demonstrated by FluoroJade B and TUNEL stains this difference was equalized after chemical binding of the free or loosely bound zinc ions in the ZEN neurons. Further support was gained by the fact that no statistical difference was found in the number of apoptotic neurons between the ZnT3-KO and WT mice exposed to DEDTC and selenium. The observation that the longer period of chemical blocking of zinc ions in zinc-selenide nanocrystals (as opposed to the shorter living zinc-DEDTC molecules) resulted in an increase in the number of GFAP positive cells in the ZnT3-KO mice suggests that the effects of zinc ions might be far more multifarious than hitherto envisaged and possibly that zinc ions are an important part of controlling post TBI inflammation.

---

**Figure 3. Control sections.** Sections are toluidine stained in (A-H). Both the WT mice and The ZnT3-KO mice display a normal morphology 24 hours after respectively DEDTC and selenite treatment. The tissue is without oedema and the cells are all intact with normal configuration. A, B, E, F are Cryo-sections 30 μm thick. C, D, G, H are semi-thin sections 3 μm thick. No major differences between the ZnT3-KO and the WT mice are noticeable. Scale bar A, B: 100 μm. Scale bar E: 200 μm. Scale bar F: 300 μm. Scale bar C, D, G, H: 30 μm. Control sections, FJB stained (I-L). Sections I, J are pretreated with DEDTC and sections K, L are pretreated with selenite. All sections are FJB negative. Control sections, TUNEL stained (M-P). Sections M, N are pretreated with DEDTC and sections O, P are pretreated with selenite. All sections are TUNEL negative. M, P depict part of the hippocampus formation and N, O depict all the six neocortical layers. Scale bar I-P: 200 μm.

doi:10.1371/journal.pone.0010131.g003
The AMG staining seen in the neuronal somata in a zone around the lesion in ZnT3-KO mice must have an origin in the loosely bound or free zinc ions that are dynamically present in all tissues. It can also be deduced that the somata staining does not result from axonal transport when looking at the control group. The fact that the neurons in the lesion borders of the WT mice were void of zinc ions in their somata 24 hours after TBI is most likely due to the axons being disabled by the nearby cut lesion blocking the normal retrograde transport of vesicular zinc from the terminals. This transport can be traced in undamaged/ normal animals subjected to an IP or IC injection of a sodium selenite/ sodium selenide solution, 6–24 hours after the treatment, ZEN neuronal somata in the whole CNS (injected IP), or ZEN neurons projecting to the injection site (if injected IC into the brain or spinal cord), will be filled with AMG enhanced zinc-selenium nanocrystals. [7,12,13,14,18,39,45]. The only explanation for this lack of transport in a zone around the TBI lesion is therefore that the retrograde axonal transport of zinc ions has been compromised. A likely explanation of the stained somata in the TBI-ZnT3-KO mice might be that the removal of the gene for ZnT3 has in some way changed/influenced the composition of zinc transporters that populate the membranes of ZnT3-KO ZEN neurons. Anatomical studies of TBI have shown that mice with a functioning ZnT3 protein respond to TBI by increasing their terminal content of zinc in a period of 0–8 hours after TBI and that the ZnT3-KO mice exhibit a number of somata marked neurons in the same period of time [41,46]. We speculate that it is this difference in the neuronal handling/ processing of zinc ions that is responsible for the increased number of damaged neurons in the ZnT3-KO mice. This implies that having a functioning ZnT3 protein is an integral part of reducing brain damage after TBI.

For the last couple of decades it has been suggested that vesicular zinc contributes directly to neuronal damage following insults as diverse as seizure, ischemia and TBI [28,33,34]. Other studies have implied that vesicular zinc 1) is not the causative agent of neuronal damage [29,47,48], 2) that it exerts a protective effect [49], and 3) that zinc chelation provides a short-term neuroprotection (evaluated histologically), but fails to improve long-term functional outcome [50].

However, the results obtained in recent studies concerning zinc chelation have been somewhat mixed. Studies using the antibiotic/zinc chelator Clioquinol have revealed an association with this zinc chelating agent and transient global amnesia with this zinc chelating agent and transient global amnesia and antibiotic/zinc chelator Clioquinol have revealed an association. Other studies using the zinc transporter 3 and glutamate decarboxylase. Neurosci Lett 321: 37–40.

Frederickson CJ, Baudette SC, Frederickson CJ, Senisi SL, Weiss JB, et al. (2004) Method for identifying neuronal cells suffering zinc toxicity by use of a novel fluorescent sensor. J Neurosci Methods 130(1): 79–89.

Danecker G (1982) Exogenous selenium in the brain. A histochemical technique for light and electron microscopic localization of catalytic selenium bonds. Histochemistry 76(3): 281–293.

Danecker G, Stoltenberg M (2006) Silver enhancement of quantum dots resulting from (1) metabolism of toxic metals in animals and humans, (2) in vivo, in vitro and in vivo. Histochemistry 121(1): 843–854.

Pérez-Clausell J (1996) Distribution of terminal fields stained for zinc in the neocortex of the rat. J Chem Neuroanat 11(2): 99–111.

References

1. Takekda A (2000) Movement of zinc and its functional significance in the brain. Brain Res 843(3): 137–148.
2. Dinley KE, Votyakova TV, Reynolds IJ (2003) Zinc inhibition of cellular energy production: implications for mitochondria and neurodegeneration. J Neurochem 85(2): 563–570.
3. Pérez-Clausell J, Dancer G (1985) Intravascular localization of zinc in rat telencephalic boutons. A histochemical study. Brain Res 337(1): 91–98.
4. Frederickson CJ, Suh SW, Silva D, Frederickson CJ, Thompson RB (2000) Importance of zinc in the central nervous system: the zinc-containing neuron. J Nutr 130(58 Suppl.): 1473–1483.
5. Takekda A (1991) Zinc homeostasis and functions of zinc in the brain. Biometals 4(3–4): 343–351.
6. Wei G, Bough CJ, Li V, Savoy JM (2004) Characterization of extracellular accumulation of Zn2+ during ischemia and reperfusion of hippocampal slices in rat. Neuroscience 125(4): 867–877.
7. Dancer G, Stoltenberg M (2005) Zinc-specific autometallografic in vivo selenium methods: tracing of zinc-enriched (ZEN) terminals, ZEN pathways, and pools of zinc ions in a multitude of other ZEN cells. J Histochim Cytchem 53(2): 141–153.
8. Dancer G, Jo SM, Varea E, Wang Z, Cole TB, et al. (2001) Inhibitory zinc-enriched terminals in mouse spinal cord. Neuroscience 105: 941–947.
9. Wang Z, Dancer G, Kin YK, Dahlstrom A, Jo SM (2002) Inhibitory zinc-enriched terminals in the mouse cerebellum: double-immunochemistry for zinc transporter 3 and glutamate decarboxylase. Neurosci Lett 321: 37–40.
10. Paoletti P, Vergnano AM, Barbour B, Casado M (2009) Zinc at glutamatergic synapses. Neuroscience 159(1): 126–136. Epub 2008 Feb 15.
11. Frederickson CJ, Baudette SC, Frederickson CJ, Senisi SL, Weiss JB, et al. (2004) Method for identifying neuronal cells suffering zinc toxicity by use of a novel fluorescent sensor. J Neurosci Methods 130(1): 79–89.
12. Danecker G (1982) Exogenous selenium in the brain. A histochemical technique for light and electron microscopic localization of catalytic selenium bonds. Histochemistry 76(3): 281–293.
13. Danecker G, Stoltenberg M (2006) Silver enhancement of quantum dots resulting from (1) metabolism of toxic metals in animals and humans, (2) in vivo, in vitro and in vivo. Histochemistry 121(1): 843–854.
Brown CE, Dyck RH (2004) Distribution of zincergic neurons in the mouse forebrain. J Comp Neurol 479(2): 156–167.

Asaf SY, Chung SH (1984) Release of endogenous Zn²⁺ from brain tissue during activity. Nature 308(5961): 734–736.

Danscher G (1994) Dynamic changes in the stainability of rat hippocampal mossy fiber boutons after local injection of sodium sulphide, sodium selenite, and sodium diethyldithiocarbamate. In: Fredericsson C, Howell GA, Kasauni E, eds. The neurobiology of zinc. Part B. New York: Alan R. Liss Inc. pp 177–191.

Howell GA, Welch MG, Fredericsson C (1984) Stimulation-induced uptake and release of zinc in hippocampal slices. Nature 308(5961): 736–738.

Weiss JH, Sensi SL (2000) Ca²⁺-Zn²⁺ permeable AMPA or kainate receptors: possible key factors in selective neurodegeneration. Trends Neurosci 23(3): 365–371.

Wang Z, Danscher G, Kim YK, Dahlstrom A, Mook J, So S (2002) Inhibitory zinc-enriched terminals in the mouse cerebellum: double-immunohistochemistry for zinc transporter 3 and glutamate decarboxylase. Neurosci Lett 321(1–2): 37–40.

Palmiter RD, Cole TB, Quaife CJ, Findley SD (1996) ZnT-3, a putative transporter of zinc into synaptic vesicles. Proc Natl Acad Sci U S A 93(25): 14934–14939.

Wenzel HJ, Cole TB, Born DE, Schwartzkroin PA, Palmeri RD (1997) Ultrastructural localization of zinc transporter-3 (ZnT-3) to synaptic vesicle membranes within mossy fiber boutons in the hippocampus of mouse and monkey. Proc Natl Acad Sci U S A 94(23): 12676–12681.

Linkous DH, Flinn JM, Koh JY, Lanzriotti A, Berths FM, et al. (2008) Evidence that the ZnT3 protein controls the total amount of elemental zinc in synaptic vesicles. J Histochem Cytochem 56(1): 3–6, Epub 2007 Aug 21.

Cole TB, Wenzel HJ, Kafer KE, Schwartzkroin PA, Palmeri RD (1999) Elimination of zinc from synaptic vesicles in the intact mouse brain by disruption of the ZnT3 gene. Proc Natl Acad Sci U S A 96(4): 1716–1721.

Danscher G (1976) Heavy metals in the hippocampal region: Some aspects of localization, function and content with special emphasis on the effect of chelating agents. Thesis, Aarhus University.

Danscher G, Shipleby MT, Andersen P (1973) Persistent function of mossy fibre synapses after metal chelation with DEDTTC (antabuse). Brain Res 85: 522–526.

Sub SW, Jo SM, Vajda Z, Danscher G (2001) Adrenalectomy causes loss of zinc ions in zinc-enriched (ZEN) terminals and decreases seizure-induced neuronal death. Brain Res 895(1–2): 25–32.

Cole TB, Robbins CA, Wenzel HJ, Schwartzkroin PA, Palmeri RD (2000) Seizures and neuronal damage in mice lacking vesicular zinc. Epilepsy Res 39(2): 153–169.

Fredericsson C, Cujangpe MP, Fredericsson CJ (2005) Is zinc the link between compromises of brain perfusion (excitotoxicity) and Alzheimer disease's? J Alzheimer Dis 6(2): 155–169. discussion 209-215.

Sub SW, Chen JW, Motamedi M, Bell B, Listik K, et al. (2000) Evidence that synaptically-released zinc contributes to neuronal injury after traumatic brain injury. Brain Res 852(2): 268–273.

Koh JY, Suh SW, Gwag BJ, He YY, Hsu CY, et al. (1996) The role of zinc in selective neuronal death after transient global cerebral ischemia. Science 272(5264): 1013–1016.

Sørensen JC, Mattsson B, Andreasen A, Johansson BB (1998) Rapid disappearance of zinc positive terminals in focal brain damage. Brain Res 782(1–2): 265–269.

Fredericsson CJ, Hernandez MD, McGinty JF (1989) Translocation of zinc may contribute to seizure-induced death of neurons. Brain Res 480(1–2): 317–321.

Danscher G, Haug FM, Fredens K (1973) Effect of diethyldithiocarbamate (DEDTTC) on sulphide silver stained boutons. Reversible blocking of Timm's sulphide silver stain for ‘‘heavy’’ metals in DEDTTC treated rats (light microscopy). Exp Brain Res 16(5): 521–532.

Côté A, Claesson M, Peralta MR, 3rd, Lafontaine K, Pellegrini L, Toóth K (2005) Cell-type-specific action of seizure-induced intracellular zinc accumulation in the rat hippocampus. J Physiol 566(6): 821–837. Epub 2005 Mar 26.

Domínguez MI, Blasco-Ibáñez JM, Crespo C, Naché J, Marqués-Mari AI, et al. (2006) Neuronal overexcitation and implication of NMDA and AMPA receptors in a mouse model of temporal lobe epilepsy implying zinc chelation. Epilepsia 47(5): 887–899.

Valente T, Audadell C (2002) Developmental expression of ZnT3 in mouse brain: correlation between the vesicular zinc transporter protein and chelatable vesicular zinc (CVZ), cells. Glial and neuronal CVZ, cells interact. Mol Cell Neurosci 21(2): 109–204.

Slomianka L (1992) Neurons of origin of zinc-containing pathways and the distribution of zinc-containing boutons in the hippocampal region of the rat. Neuroscience 48(2): 325–352.

Danscher G, Stoltenberg M (2006) Silver enhancement of quantum dots resistant from (1) metabolism of toxic metal ions by rats and humans, (2) in vitro, in vitro and immersion created zinc-sulphur/zinc-selenium nanocrystals, (3) metal ions liberated from metal implants and particles. Prog Histochem Cytochem 41(2): 57–159. Epub 2006 Aug 7. Review.

Danscher G, Palmiter RD, Abruña H, Selegaard C, et al. (2007) Changes in the vesicular zinc pattern following traumatic brain injury. Neuroscience 150(1): 93–103.

Schmedt EC, Hopkins KJ (2000) Fluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration. Brain Res 874(2): 123–130.

Carrasco J, Penkowa M, Hadberg H, Molinero A, Hidalgo J (2000) Enhanced seizures and hippocampal neurodegeneration following kainic acid-induced seizures in metallothionein-I + II-deficient mice. Eur J Neurosci 12(7): 2311–2322.

Larsen A, Kolind K, Pedersen DS, Doering P, Pedersen MO, et al. (2000) Gold ions bio-released from metallic gold particles reduce inflammation and apoptosis and increase the regenerative responses in focal brain injury. Histochem Cell Biol 110(4): 681–92. Epub 2000 Jun 10.

Wang Z, Li JY, Dahlstrom A, Danscher G (2001) Zinc-enriched GABAAergic terminals in mouse spinal cord. Brain Res 921: 163–172.

Yeiser EC, Lenzant AA, Casto RM, Lewenson CW (1999) Free zinc increases at the site of injury after cortical stab wounds in mature but not immature rat brain. Neurosci Lett 277(2): 75–78.

Lee JY, Cole TB, Palmeri RD, Koh JY (2000) Accumulation of zinc in degenerating hippocampal neurons of ZnT3-null mice after seizures: evidence for synaptic zinc release. Neurobiol Dis 7(4): 251–260.

Lee JY, Kim JH, Palmeri RD, Koh JY (2003) Zinc released from metallothionein-iii may contribute to hippocampal CA1 and thalamic neuronal death following acute brain injury. Exp Neurol 141(1): 357–347.

Kazumura Y, Ina Y, Abe J, Ueda M, Mifune M, et al. (2006) Protective effect of zinc against ischemic neuronal injury in a middle cerebral artery occlusion model. J Pharmaco Sci 100(2): 142–148.

Hellmich HL, Edson K, Cowart J, Crookshanks J, Boone DK, et al. (2008) Chelation of neurotoxic zinc levels does not improve neurobehavioral outcome after traumatic brain injury. 1: Neurosci Lett 440(2): 153–9. Epub May 23.

Ismail T, Mauzerhofer E, Slomianka L (2008) The hippocampal region of rats and mice after a single i.p. dose of choquinol: loss of synaptic zinc, cell death and c-Fos induction. Neuroscience 157(3): 697–707. Epub 2008 Sep 11.

Stoltenberg M, Bush AL, Bach G, Snidt K, Larsen A, et al. (2007) Amyloid plaques arise from zinc-enriched cortical layers in APP/PS1 transgenic mice and are paradoxically enlarged with dietary zinc deficiency. Neuroscience 153(2): 357–369.

Maret W (2009) Molecular aspects of human cellular zinc homeostatic redox control of zinc potentials and zinc signals. Biomolecules 22(1): 149–157. Epub 2009 Jan 7.

Bitounhrave BK, Cunningham MG (2009) Zinc: the brain’s dark horse. Synapse 63(11): 1029–1049.

Yeiser EC, Vanlandingham JW, Lewenson CW (2002) Moderate zinc deficiency increases cell death after brain injury in the rat. Nutr Neurosci 5(3): 345–352.

Lee JM, Zipfel GJ, Park KH, He YY, Hsu CY, et al. (2002) Zinc translocation accelerates infection after mild transient focal ischemia. Neuroscience 115(3): 871–878.

Suh SW, Fredericsson CJ, Danscher G (2006) Neurotoxic zinc translocation into hippocampal neurons is inhibited by hypothermia and is aggravated by hyperthermia after traumatic brain injury in rats. J Cereb Blood Flow Metab 26(2): 161–169.